Akero Therapeutics ( (AKRO) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Akero Therapeutics’ stock has been on the rise due to the promising potential of its clinical asset, Efruxifermin, which is showing superior efficacy in Phase 3 studies for treating metabolic dysfunction-associated steatohepatitis. This has set the company apart in the F4 cirrhosis market. In response to these developments, Clear Street initiated coverage with a Buy rating, while H.C. Wainwright raised its price target, citing strong financials and clinical progress. Morgan Stanley also adjusted its price target based on market expectations and anticipated performance.
More about Akero Therapeutics
YTD Price Performance: 50.18%
Average Trading Volume: 1,110,529
Technical Sentiment Signal: Strong Sell
Current Market Cap: $3.36B
For further insights into AKRO stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.